Equities analysts predict that Endologix, Inc. (NASDAQ:ELGX) will report $35.26 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Endologix’s earnings, with estimates ranging from $35.00 million to $35.58 million. Endologix posted sales of $34.76 million during the same quarter last year, which suggests a positive year-over-year growth rate of 1.4%. The company is scheduled to announce its next earnings report on Thursday, November 7th.
According to Zacks, analysts expect that Endologix will report full year sales of $142.70 million for the current year, with estimates ranging from $142.10 million to $143.85 million. For the next financial year, analysts anticipate that the firm will report sales of $150.91 million, with estimates ranging from $150.00 million to $152.07 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Endologix.
Endologix (NASDAQ:ELGX) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.43. The company had revenue of $36.24 million during the quarter, compared to analysts’ expectations of $36.09 million. Endologix had a negative net margin of 60.32% and a negative return on equity of 120.57%.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its position in Endologix by 8.9% in the 4th quarter. BlackRock Inc. now owns 6,208,597 shares of the medical instruments supplier’s stock valued at $4,446,000 after buying an additional 509,493 shares during the period. Northern Trust Corp boosted its position in Endologix by 15.9% in the 4th quarter. Northern Trust Corp now owns 1,215,671 shares of the medical instruments supplier’s stock valued at $871,000 after buying an additional 166,409 shares during the period. Geode Capital Management LLC boosted its position in Endologix by 22.9% in the 4th quarter. Geode Capital Management LLC now owns 1,059,281 shares of the medical instruments supplier’s stock valued at $757,000 after buying an additional 197,351 shares during the period. Two Sigma Advisers LP boosted its position in Endologix by 79.5% in the 4th quarter. Two Sigma Advisers LP now owns 249,082 shares of the medical instruments supplier’s stock valued at $178,000 after buying an additional 110,300 shares during the period. Finally, Bank of America Corp DE boosted its position in Endologix by 880.9% in the 4th quarter. Bank of America Corp DE now owns 552,431 shares of the medical instruments supplier’s stock valued at $395,000 after buying an additional 496,113 shares during the period. Institutional investors own 48.44% of the company’s stock.
ELGX traded down $0.01 during midday trading on Friday, reaching $6.10. 242,300 shares of the company’s stock were exchanged, compared to its average volume of 261,542. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.53 and a quick ratio of 0.90. The stock has a market capitalization of $112.90 million, a PE ratio of -0.85 and a beta of 0.37. The business’s 50-day moving average price is $6.75 and its 200 day moving average price is $5.69. Endologix has a 1-year low of $5.20 and a 1-year high of $26.50.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.